Serum Institute Awaits WHO Emergency Approval For AstraZeneca Shot Soon
Business | Edited by Nirmalya Sen | Thursday January 14, 2021
The World Health Organization (WHO) listed Pfizer and BioNTech's Covid-19 shot for emergency use on December 31 as it sought to accelerate vaccination in the developing world, which is badly lagging Western countries
"Fantastic News": UK Minister On Oxford-AstraZeneca Vaccine Announcement
World News | Reuters | Monday November 23, 2020
British Health Secretary Matt Hancock said it was "fantastic news" that data on Monday showed that a COVID-19 vaccine developed by AstraZeneca with Oxford University could be up to 90% effective and reduce its transmission.
Oxford Vaccine Can Be 90% Effective; Serum Institute Is India Partner
World News | Reuters | Monday November 23, 2020
AstraZeneca said on Monday its COVID-19 vaccine could be around 90% effective, giving the world another weapon to fight the global pandemic and potentially cheaper to make, easier to distribute and faster to scale-up than rivals. The combined analysis from both dosing regimens resulted in an average efficacy of 70%.
Serum Institute Awaits WHO Emergency Approval For AstraZeneca Shot Soon
Business | Edited by Nirmalya Sen | Thursday January 14, 2021
The World Health Organization (WHO) listed Pfizer and BioNTech's Covid-19 shot for emergency use on December 31 as it sought to accelerate vaccination in the developing world, which is badly lagging Western countries
"Fantastic News": UK Minister On Oxford-AstraZeneca Vaccine Announcement
World News | Reuters | Monday November 23, 2020
British Health Secretary Matt Hancock said it was "fantastic news" that data on Monday showed that a COVID-19 vaccine developed by AstraZeneca with Oxford University could be up to 90% effective and reduce its transmission.
Oxford Vaccine Can Be 90% Effective; Serum Institute Is India Partner
World News | Reuters | Monday November 23, 2020
AstraZeneca said on Monday its COVID-19 vaccine could be around 90% effective, giving the world another weapon to fight the global pandemic and potentially cheaper to make, easier to distribute and faster to scale-up than rivals. The combined analysis from both dosing regimens resulted in an average efficacy of 70%.
................................ Advertisement ................................
................................ Advertisement ................................
